Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. announced that University Hospital Zurich has begun an independent clinical study on Steriwave, their nasal decolonization technology, to combat surgical site infections (SSI). This study, led by Professor Dr. Harald Essig, aims to evaluate the efficacy of Steriwave in reducing preoperative nasal microbial burden, which is crucial for preventing SSIs and hospital-acquired infections. Steriwave is a light-activated antimicrobial treatment that offers a fast-acting alternative to traditional antibiotics, working within a single five-minute treatment. This initiative is part of Ondine’s mission to provide innovative solutions for infection prevention and address antimicrobial resistance.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has developed a range of investigational products using its proprietary technology, including the Steriwave nasal photodisinfection system, which is approved in several countries and is undergoing clinical trials in the US.
Average Trading Volume: 267,855
Technical Sentiment Signal: Buy
Current Market Cap: £41M
See more insights into OBI stock on TipRanks’ Stock Analysis page.